Quintrio
Home

SERVICES-HEALTH SERVICES

GeneDx Holdings Corp. Class A Common Stock

WGS

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Last trade $46.64
Day change -$4.38 (-8.58%)
Day range $44.34 – $51.99
Volume 1,414,627
Market cap $1.53B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.53B
Price / earnings
—
Price / book
6.25×
Price / sales
3.32×
EV / sales
3.43×
EV / EBITDA
-38.52×

Profitability

Earnings per share
-$3.71
Return on assets
-21.14%
Return on equity
-45.49%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.6×
Current ratio
4.16×
Quick ratio
3.85×
Cash ratio
1.35×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$101.22M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for WGS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$123.1M$114.44M$102.25M$120.99M$116.74M$102.69M$87.12M$95.64M
Cost of revenue$37.04M$36.2M$34.04M$36.72M$32.22M$31.79M$28.64M$29.44M
Gross profit$86.06M$78.24M$68.21M$84.27M$84.53M$70.9M$58.48M$66.21M
Selling, general and administrative$79.12M$76.04M$74.59M$73.96M$67.95M$46.86M$50.45M$45.81M
Research and development$17.37M$19.66M$19.8M$24.54M$19.83M$15.08M$12.58M$11.59M
Total operating expenses$96.49M$95.69M$125.68M$98.5M$87.78M$61.94M$63.03M$57.4M
Operating income-$10.43M-$17.46M-$57.47M-$14.24M-$3.25M$8.96M-$4.55M$8.81M
Interest expense-$1.78M-$1.19M-$717K$0-$562K-$817K-$640K$0
Income before taxes-$12.3M-$18.26M-$62.42M-$18.23M-$7.39M$10.56M-$6.08M$5.41M
Income taxes$26K-$518K$897K-$564K$247K-$246K$447K-$24K
Net income-$12.33M-$17.74M-$63.32M-$17.67M-$7.64M$10.81M-$6.53M$5.44M
Net income attributable to common shareholders-$12.33M-$17.74M-$63.57M-$17.67M-$7.64M$10.81M-$6.45M$5.44M
EBITDA-$3.53M-$10.74M-$19.38M-$7.35M$3.22M$15.15M$1.13M$14.36M
Basic earnings per share-$0.41-$0.60-$2.16-$0.61-$0.27$0.38-$0.23$0.20
Diluted earnings per share-$0.41-$0.60-$2.16-$0.63-$0.27$0.36-$0.23$0.20

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Why GeneDx Holdings Stock Just Dropped 16.6%

GeneDx Holdings stock fell 16.6% after the company reported Q3 results that met revenue expectations at $123.1 million but fell short on testing volume growth. The company lowered its 2026 volume growth target to at least 28% from the previously promised 29.2% or more, marking the second downward revision this year. While the genetic testing company continues to grow, investors are concerned about the deceleration in core business metrics.

Zacks Investment Research

GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates

GeneDx Holdings (WGS) reported quarterly earnings of $0.28 per share, significantly beating consensus estimates of $0.07, representing a 300% surprise. However, the stock has underperformed the market by 52.1% year-to-date. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Agilon Health (AGL) Q3 Earnings and Revenues Surpass Estimates

Agilon Health (AGL) reported quarterly earnings of $1.97 per share, significantly beating consensus estimates of a loss of $2.01 per share, representing a +198% earnings surprise. The company posted revenues of $1.52 billion, surpassing estimates by 4.43%. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Agilon shares have gained 409.9% year-to-date, substantially outperforming the S&P 500's 10.6% gain.

Zacks Investment Research

Encompass Health Expands Rehab Footprint With New Maine Hospital

Encompass Health Corporation (EHC) opened its first wholly owned hospital in Maine with 50 inpatient rehabilitation beds. Q2 2026 discharges rose 5.6% year-over-year, driven by new capacity and 2.8% same-store growth. EHC opened three hospitals in the first half of 2026 and plans to open eight new hospitals throughout the year, reflecting its strategy to expand capacity in favorable markets.

Zacks Investment Research

Should You Invest in the State Street SPDR S&P Health Care Services ETF (XHS)?

The State Street SPDR S&P Health Care Services ETF (XHS) is a passively managed healthcare services sector ETF with low costs (0.35% expense ratio) and solid year-to-date performance of 27.29%. The fund holds about 62 healthcare companies with a medium risk profile (beta of 0.93) and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable option for investors seeking diversified healthcare sector exposure.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 4, 20231-for-33reverse split